Imexpharm Pharmaceutical Joint Stock Co (coded IMP) has estimated that its total revenue touched 215 billion dong in Jan-June, up 13.3 percent against the same period last year, and a pre-tax profit of 37.5 billion dong, increasing 19 percent year-on-year.
The company’s Cephalosporine Factory in Binh Duong province is expected to officially start operation in Q4 of 2009. This factory, with investment capital of 110 billion dong, will manufacture liquid antibiotics. It’s estimated that the factory will bring in 200 billion dong of yearly revenue for the company and will help retain the company’s growth rate of 10 percent per year.
At present, IMP is finishing the registration profile for establishing Remedica Co Ltd, a new company that will focus on researching, preserving and developing herbs in Dong Thap Muoi.